Literature DB >> 29122544

Population Health Management for Inflammatory Bowel Disease.

Parambir S Dulai1, Siddharth Singh2, Lucilla Ohno-Machado3, William J Sandborn4.   

Abstract

Inflammatory bowel diseases (IBDs) are chronic and impose significant, multidimensional burdens on patients and health care systems. The increasing prevalence of IBD will only worsen this problem globally-population health management (PHM) strategies are needed to increase quality of care and population health outcomes while reducing health care costs. We discuss the key components of PHM in IBD. Effective implementation of PHM strategies requires accurate identification of at-risk patients and key areas of variability in care. Improving outcomes of the at-risk population requires implementation of a multicomponent chronic care model designed to shift delivery of ambulatory care from acute, episodic, and reactive encounters, to proactive, planned, long-term care. This is achieved through team care of an activated patient with the help of remote monitoring, clinical information systems, and integrated decision support, with accompanying changes in delivery systems. Performance measurement is integral to any PHM strategy. This involves developing and implementing meaningful metrics of different phases of quality of IBD care and measuring them efficiently using modern clinical information systems. Such an integrated framework of PHM in IBD will facilitate the delivery of high-value care to patients.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammatory Bowel Disease; Population Health; Quality; Value

Mesh:

Year:  2017        PMID: 29122544     DOI: 10.1053/j.gastro.2017.09.052

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  21 in total

Review 1.  Redefining the IBDs using genome-scale molecular phenotyping.

Authors:  Terrence S Furey; Praveen Sethupathy; Shehzad Z Sheikh
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-05       Impact factor: 46.802

2.  No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

Authors:  Siddharth Singh; James A Proudfoot; Parambir S Dulai; Vipul Jairath; Mathurin Fumery; Ronghui Xu; Brian G Feagan; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2018-06-21       Impact factor: 10.864

Review 3.  Evolution of Clinical Trials in Inflammatory Bowel Diseases.

Authors:  Siddharth Singh
Journal:  Curr Gastroenterol Rep       Date:  2018-08-04

4.  Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases.

Authors:  Nghia H Nguyen; Jejo Koola; Parambir S Dulai; Larry J Prokop; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-27       Impact factor: 11.382

5.  No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy.

Authors:  Siddharth Singh; Jihoon Kim; Wenhong Zhu; Parambir S Dulai; William J Sandborn; Vipul Jairath
Journal:  Aliment Pharmacol Ther       Date:  2020-06-23       Impact factor: 8.171

Review 6.  Head-to-head trials in inflammatory bowel disease: past, present and future.

Authors:  Lieven Pouillon; Simon Travis; Peter Bossuyt; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-17       Impact factor: 46.802

7.  Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.

Authors:  Nghia H Nguyen; Ivonne Martinez; Ashish Atreja; Amy M Sitapati; William J Sandborn; Lucila Ohno-Machado; Siddharth Singh
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

8.  US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease.

Authors:  Berkeley N Limketkai; Siddharth Singh; Vipul Jairath; William J Sandborn; Parambir S Dulai
Journal:  Inflamm Bowel Dis       Date:  2019-10-18       Impact factor: 5.325

9.  Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016.

Authors:  Siddharth Singh; Alexander S Qian; Nghia H Nguyen; Stephanie K M Ho; Jiyu Luo; Vipul Jairath; William J Sandborn; Christopher Ma
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 7.290

10.  Cost-Related Nonadherence to Medications Among US Adults With Chronic Liver Diseases.

Authors:  Carlos Lago-Hernandez; Nghia H Nguyen; Rohan Khera; Rohit Loomba; Sumeet K Asrani; Siddharth Singh
Journal:  Mayo Clin Proc       Date:  2021-06-11       Impact factor: 11.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.